O repositorio dixital RUNA

    • Español
    • Galego
    • English
  • Galego 
    • Español
    • Galego
    • English
  • Login
RUNABibliosaúdeXunta de galicia. Consellería de sanidadeServicio Galego de saúde
  • REPOSITORIO
  • SOBRE NÓS
    • Sobre RUNA
    • Normativa
    • Política Sergas
  • AXUDA
    • Axuda
    • FAQ
  •   RUNA Principal
  • Publicación científica
  • Ver ítem
JavaScript is disabled for your browser. Some features of this site may not work without it.

Changing pattern of the use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Sanchez-Piedra, C.; Prior-Espanol, A.; Gonzalez, M. F.; Colazo, M.; Ruiz-Montesinos, D.; Perez-Vera, Y.; Ortiz, A.; Bustabad, S.; Vela-Casasempere, P.; Rojas-Gimenez, M.; Sanchez-Alonso, F.; Diaz-Gonzalez, F.; Gómez-Reino Carnota, Juan Jesús
Thumbnail
Estatísticas
Estatísticas
Ver Estatísticas de uso
Identificadores
Identificadores
URI: http://hdl.handle.net/20.500.11940/15730
DOI: 10.1136/annrheumdis-2019-eular.3181
ISSN: 0003-4967
Rexistro completo
Servizos
Servizos
RISMendeleyLinksolver
Visualización ou descarga de ficheiros
Visualización ou descarga de ficheiros
Acceso a la versión del editor (120.2Kb)
Ann Rheum Dis. 2019;78(suppl 2):1151-1152 (1.062Mb)
Autor corporativo
Biobadaser Group
Data de publicación
2019
Título da revista
Annals of the rheumatic diseases
Tipo de contido
Publicación de congreso
Resumo
Background: During the last 15 years, the comprehensive understanding of the safety, effectiveness, expanding access, and availability of new biologic disease-modifying antirheumatic drugs (bDMARDs) has likely contributed to the pattern of use of these compounds in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Objectives: To assess changes in the baseline characteristics of patients who underwent biological therapy from 2007 to 2018 in a real world setting. Methods: Data were obtained from BIOBADASER, the Spanish registry of biologics. Recorded data is obtained from routine clinical practice. Patients diagnosed with RA, PsA and AS and who started biological treatment from 2007 to 2018 were included. Sociodemographic and clinical variables, as well as first bDMARD used, were stratified by the starting year period (2007-2009; 2010-2012; 2013-2015; 2016-2018) and compared using Anova and Chi-square tests. Results: 6943 patients (2827 RA patients, 1274 PsA and 1261 AS) were included in this analysis (Table 1). Patient age at the beginning of the first biologic was significantly higher during the period 2016-2018 than in 2007-2009 (48.3 vs 50.6). Disease duration until the use of biologics decreased from 8.6 to 8.1 years. In RA patients, disease activity, as assessed by DAS28 at the start of the biological treatment, was significantly higher in the 2007-2009 period than in the last period analyzed (5.1 vs 4.7). The use of TNF inhibitor as a first option also changed significantly (94.6% vs 58.5%). Regarding comorbidities, the number of rheumatic patients treated with biologics and a past history of cancer (1.8% vs 3.7%), ischemic heart disease (1.8% vs 3.1%), hypercholesterolemia (13.6% vs 26.1%), or hypertension (21.7% vs 23.7%) has increased significantly. Conclusion: Our data show that during the last decade the pattern of use of biologics in patients with rheumatic diseases has changed. Nowadays these compounds are used in older patients, with shorter disease duration, with lower disease activity in RA, and with more comorbidities.

Navega

Todo RUNAColecciónsCentrosAutoresTítulosDeCSMeSHCIETipo de contidoEsta colecciónCentrosAutoresTítulosDeCSMeSHCIETipo de contido

Estatísticas

Ver Estatísticas de uso

DE INTERESE

Sobre Acceso AbertoDereitos de autor
TwitterRSS
Xunta de Galicia
© Xunta de Galicia. Información mantida e publicada na internet pola Consellería de Sanidade o Servizo Galego de Saúde
Aviso legal | RSS
Galicia